

QIBA PET Amyloid Biomarker Committee

30 January 2015 at 9:00 AM CT (GMT-6)

Call Summary

In attendance:

Co-chairs:

Satoshi Minoshima, MD, PhD

Eric Perlman, MD

Anne Smith, PhD

Participants:

Christopher Buckley, PhD

Santiago (Santi) Bullich, PhD

Susan De Santi, PhD

John Hoffman, MD

Paul Kinahan, PhD, FIEEE

Gregory Klein, PhD

Adriaan Lammertsma, PhD

Dawn Matthews, MS, MBA

P. David Mozley, MD

Nancy Obuchowski, PhD

Amy Perkins, PhD

Sandra Sanabria, PhD

Rathan Subramaniam, MD, PhD

Daniel Sullivan, MD

Jean-Luc Vanderheyden, PhD

Richard Wahl, MD, FACR

Brian Zimmerman, PhD

RSNA

Joe Koudelik

Julie Lisecki

Call Summary Points and Action Items:

- Dr. Kinahan provided a Round-4 project update
 - The Amyloid physical phantom and DRO projects are on track; a database to use in conjunction with the phantom has been procured via the University of Washington
- A statistical expert is needed to help with analysis of the meta-analysis toward informing the Profile claim language
- The most current version of the Profile is Version 0.09, 24 November 2014
- Dr. Subramaniam is in the process of conducting a meta-analysis on 700+ articles
 - Data will be extracted for the analysis and will likely take 4-5 weeks, with a focus on repeatability coefficients and tracer identification
 - Goal is to find commonalities among tracers with 3 prominent contenders
 - The top three tracers will be analyzed for their respective pros and cons and reviewed for manufacturer protocols
- The Hoffman phantom (and possibly uniformity & resolution phantoms will be used as standards in Profile version 1.0.
- Compliance and field testing issues will need to be addressed more completely as Profile writing continues. Consider inviting lead members of CT Volumetry committee on future teleconference to present their work on field testing.
- Discussed writing Profile using small teams, and these are current sub-groups and members
 - **Claims Sub-group (test-retest, meta-analysis)**
 - Dr. Rathan Subramaniam (plus others at Johns Hopkins)
 - Dr. Kirk Frey
 - Dr. Nancy Obuchowski
 - **Image Analysis Sub-group**
 - Ms. Dawn Matthews (team lead)
 - Dr. Satoshi Minoshima
 - **Site Certification Sub-group**

- Dr. Greg Klein (team lead)
- Dr. Paul Kinahan
- Dr. John Sunderland (volunteered, needs to accept)
- Dr. Ronald Boellaard (volunteered, needs to accept)
- Dr. Anne Smith

AICED PET Registry – CMS Proposal (Dr. Minoshima)

- Awaiting response from CMS
- Issues of site and reader qualification to be determined

2015 Human Amyloid Imaging (HAI) Conference Update (Dr. Smith)

- Interesting statistic from the conference: A Lilly Amyloid therapeutic is projected to reach market by 2018; yearly treatment cost per patient expected to be \$20,000

Request for committee members to provide chairpersons information regarding how outside activities in Amyloid PET and Alzheimer's disease community might impact needed revisions or additions to Profile content.

Upcoming Proposed Nuclear Medicine Calls (Fridays, 9 am CT):

- **February 6:** SPECT Task Force (FDG-PET Biomarker Committee members invited)
- **February 13:** PET Amyloid Biomarker Ctte
- **February 20:** SPECT Task Force
- **February 27:** PET Amyloid Biomarker Ctte